Biren Amin, MBA
Mr. Amin joins Immuneering after having built a strong track record for nearly two decades on Wall Street covering small and mid-cap biotechnology companies focused on oncology, central nervous system disorders, ophthalmology, and rare diseases. Prior to Immuneering, Mr. Amin spent nearly 10 years at Jefferies as Managing Director of Biotechnology Research. Previously, he spent time at other equity research firms such as WJB Capital Group, FTN Equity Markets, Stanford Financial, and Prudential Equity Group. Mr. Amin started his career at Aventis Pharma where he was Senior Manager in their scientific competitive intelligence group with business development. He holds an M.B.A. from Stern School of Business at New York University, a M.S. in Pharmacy from Long Island University, and a B.S. in Pharmacy from University of the Sciences in Philadelphia.
